Trade

with

MEI Pharma Inc
(NASDAQ: MEIP)
AdChoices
7.98
+0.08
+1.01%
After Hours :
-
-
-

Open

7.96

Previous Close

7.90

Volume (Avg)

36.08k (65.38k)

Day's Range

7.95-8.09

52Wk Range

5.51-13.98

Market Cap.

171.78M

Dividend Rate ( Yield )

-

Beta

1.31

Shares Outstanding

21.61M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -27.15M

    • Market Cap.

    • 171.78M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.31

    • Forward P/E

    • -5.78

    • Price/Sales

    • -

    • Price/Book Value

    • 3.80

    • Price/Cash flow

    • -7.92

      • EBITDA

      • -27.10M

      • Return on Capital %

      • -62.88

      • Return on Equity %

      • -67.82

      • Return on Assets %

      • -62.88

      • Book Value/Share

      • 2.09

      • Shares Outstanding

      • 21.61M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 16.00

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -1.34

        • Cashflow Estimate

        • -1.17

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 10.68

              • 1.52

              • Quick Ratio

              • 10.57

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.10

              • 1.91

              • Book Value/Share

              • 2.09

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.68

                • 63.29

                • P/E Ratio 5-Year High

                • -43.01

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.46

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.53

                • Price/Book Value

                • 3.67

                • 3.31

                • Price/Cash Flow Ratio

                • -7.92

                • 21.23

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -67.82

                        (-115.50)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -62.88

                        (-83.00)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -67.82

                        (-115.50)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • -

                      • 1.80

                      • Asset Turnover

                      • -

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -27.23M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -7.92
                      Ownership

                      Institutional Ownership

                      72.57%

                      Top 10 Institutions

                      64.41%

                      Mutual Fund Ownership

                      30.75%

                      Float

                      62.50%

                      5% / Insider Ownership

                      0.11%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • JPM Global Healthcare

                      •  

                        1,200,944

                      • 0.00

                      • 5.56

                      • Franklin Biotechnology Discovery

                      •  

                        917,702

                      • 153.79

                      • 4.25

                      • Fidelity Advisor® Capital Development

                      •  

                        877,019

                      • 0.00

                      • 4.06

                      • Fidelity® Large Cap Stock Fund

                      •  

                        816,734

                      • 0.00

                      • 3.78

                      • Fidelity Advisor® Diversified Stock Fund

                      •  

                        600,000

                      • 0.00

                      • 2.78

                      • Franklin Biotechnology Discovery Fund

                      •  

                        412,365

                      • 0.00

                      • 1.91

                      • Fidelity Advisor® Large Cap Fund

                      •  

                        290,603

                      • 2.76

                      • 1.34

                      • Vanguard Total Stock Mkt Idx

                      •  

                        269,246

                      • 0.00

                      • 1.25

                      • Tekla Life Sciences Investors

                      •  

                        243,920

                      • 0.00

                      • 1.13

                      • Candriam Eqs L Biotechnology

                      •  

                        225,000

                      • 0.00

                      • 1.04

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        2,565,896

                      • -10.72%

                      • 11.88

                      • New Leaf Venture Management II, LLC

                      •  

                        2,045,475

                      • -88.64%

                      • 11.95

                      • Orbimed Advisors, LLC

                      •  

                        1,924,500

                      • 0.00%

                      • 8.91

                      • Visium Asset Management LLC

                      •  

                        1,660,626

                      • 0.00%

                      • 7.69

                      • Franklin Advisers, Inc.

                      •  

                        1,330,067

                      • +53.94%

                      • 6.16

                      • J P Morgan Asset Management (UK) Ltd

                      •  

                        1,200,944

                      • 0.00%

                      • 5.56

                      • Deerfield Management Co

                      •  

                        1,132,376

                      • -2.76%

                      • 5.24

                      • Aisling Capital LLC

                      •  

                        770,000

                      • 0.00%

                      • 3.56

                      • Vanguard Group, Inc.

                      •  

                        477,301

                      • -4.01%

                      • 2.21

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Distressed

                      Style

                      Small Growth

                      MEI Pharma Inc was incorporated in Delaware in 2000. The company a development-stage oncology company engaged in the clinical development of novel small molecules for the treatment of cancer based on the central design of naturally o...moreccurring compounds called isoflavones. These compounds interact with specific enzyme targets resulting in inhibition of tumor cell metabolism – a function critical for the survival of cancer cells. The company is currently focused on the clinical development of three drug candidates, ME-143, ME-344 and Pracinostat. In May 2011, it completed the acquisition of certain assets and intellectual property, including those related to ME-143 and ME-344, from Novogen, in accordance with the terms of an Asset Purchase Agreement, dated as of December 21, 2010, between the company, ...moreNovogen and Novogen Research Pty Limited. The U.S. Patent and Trademark Office (USPTO) issued a new patent covering a number of its isoflavone-based compounds, including ME-143 and ME-344, and their pharmaceutical compositions until March 2027. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.lessless

                      Key People

                      Daniel P. Gold,PhD

                      CEO/Director/President

                      Mr. Thomas Zech

                      CFO/Chief Accounting Officer/Secretary

                      Dr. Thomas C. Reynolds,M.D.,PhD

                      Director

                      William D. Rueckert

                      Director

                      Dr. Christine A. White,M.D.

                      Director

                      • MEI Pharma Inc

                      • 11975 El Camino Real

                      • San Diego, CA 92130

                      • USA.Map

                      • Phone: +1 858 792-6300

                      • Fax: -

                      • meipharma.com

                      Incorporated

                      2000

                      Employees

                      19

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: